Shilpa Medicare has informed the exchanges that the US FDA has completed inspection of the company’s API Unit-I and Unit-II at Raichur, Karnataka, between January 16 and 19. The FDA concluded the inspection with three Form 483 observations. Shilpa Medicare is in the process of submission of a corrective and preventive action (CAPA) plan to the regulator within the stipulated timelines in response to the Form 483 issued at the end of inspection. The stock of Shilpa Medicare gained 2.3 per cent at ₹600.50 on the NSE.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.